Skip to main content



Product Overview

Type:                                     COVID-19 Vaccine (Ad5-nCoV-S [Recombinant]) 

INN:                                       N/A

Commercial name:              Convidecia

EUL holder:                          CanSino Biologics Inc.

Country:                                People’s Republic of China

Responsible NRA:                National Medical Products Administration (NMPA)  

Country:                                People’s Republic of China


WHO EUL recommendation

Effective date:           19 May 2022

Recommendation for an Emergency Use Listing (EUL) of Convidecia COVID-19 Vaccine (Ad5/nCoV-5[recombinant]) submitted by CanSino Biologics Inc. (Published: 10 October 2022)


Product description

Pharmaceutical Form:            Sterile solution for injection

Presentation:                            2 mLVial

Number of doses:                     1 and 3 doses of 0.5 mL

Route of administration:         Intramuscular

Age indication:                         Individuals 18 to 59 years of age

Shelf – life:                                12 months

Storage temperature:               2°C to 8°C

Vaccine Vial monitor (VVM):  None

Preservative:                              None

Diluent:                                         None

Special storage conditions:     Not applicable

Handling of opened multi-dose vials: 

WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first.


Packaging description

Secondary Packaging:

Box containing 40 vials (40 doses). Dimensions: 4.4 x 15.6 x 9.5 cm

Tertiary Packaging:

a. Carton containing 18 secondary boxes (58 vials/720 doses). Dimensions: 17x49.3x21.7 cm.

b. Carton containing 30 secondary boyes (1200 vials/1200 doses). Dimensions: 25.5x34x31.5 cm. 

Cold Chain Volume: 16.30 cm3/dose      (in secondary packaging)